Combination therapy and radiation for EGFR-mutant lung cancer after resistance
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IV non-small cell lung cancer with an EGFR mutation (L858R or 19del).
- Your cancer must have stopped responding to first-line treatment with a third-generation EGFR-targeted pill.
- You should be in generally good health, able to perform daily activities with little to no help (ECOG 0–1).
- You need at least one tumor that can be measured on scans.
- If you have brain metastases, they must be stable and not causing symptoms, and you must not need steroids for them.
- Your kidneys, liver, and blood counts need to be within safe limits as checked by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding focused radiation therapy to the spots of cancer that remain after your first treatment (an EGFR pill plus chemo) can help control advanced lung cancer better. It is for people whose cancer has an EGFR mutation and who have only a few residual spots, with the goal of delaying progression and improving outcomes.
This study tests a combination of two targeted therapy pills (andamertinib and anlotinib) for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has progressed after taking a previous targeted therapy. The goal is to see if this new combination can stop the cancer from growing.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
This trial tests combining a targeted pill (EGFR-TKI) with an antibody drug (bevacizumab) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if this combination works better than the pill alone as a first treatment.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.